Bland de senaste upptäckterna av vad Reg Med kan göra kom i förra veckan en ganska uppseväckande studie om Reg Med och diabetes. Forskare från Australien har visat att med Reg Med kan man få en diabetespatient att börja tillverka eget insulin. Via stamceller från bukspottskörteln har de fått igång insulinproduktionen hos en diabetespatient. Vad det innebär? Jo,en ganska dramatisk skillnad då den drabbade slipper alla dessa medikamenter som måste intas,som exempelvis dessa infernaliska insulinsprutor man måste ta varje dag. Infolänk
Media release
Researchers are zeroing in on the ultimate quest to regenerate insulin in pancreatic stem cells and replace the need for regular insulin injections.
Baker Heart and Diabetes Institute researchers have demonstrated in a Nature scientific journal that newly made insulin cells can respond to glucose and produce insulin following stimulation with two US Food and Drug Administration-approved drugs in as little as 48 hours.
Further, they confirmed this pathway of awakening the insulin-producing cells is viable in age groups from 7 to 61, providing much-needed insights into the mechanisms underlying the regeneration of beta cells.
Using pancreatic cells derived from a child and adult type 1 diabetic donors, and from a non-diabetic person, a team led by Professor Sam El-Osta demonstrated how insulin-producing cells that are destroyed in people with type 1 diabetes can be regenerated into glucose sensing and functionally secreting insulin cells.
In this latest study by the Human Epigenetics team, they show small molecule inhibitors that are currently used for rare cancers and approved by the US FDA can rapidly return insulin production in pancreatic cells destroyed by diabetes.
While current pharmaceutical options for diabetes treatment help control blood glucose levels they do not prevent, stop or reverse the destruction of insulin-secreting cells.
The novel therapeutic approach holds the potential to become the first disease modifying treatment for type 1 diabetes by facilitating glucose responsive insulin production by harnessing the patient’s remaining pancreatic cells, thereby enabling people living with diabetes to potentially achieve independence from round-the-clock insulin injections.
This disease-modifying treatment also represents a promising solution for the significant number of Australian’s living with insulin dependent diabetes, who account for 30 per cent of those with type 2 diabetes.
The development of novel pharmacological therapies aimed at restoring pancreas function addresses the stark reality of donor organ shortages.
“We consider this regenerative approach an important advance towards clinical development,” Professor El-Osta said. “Until now, the regenerative process has been incidental, and lacking confirmation, more importantly the epigenetic mechanisms that govern such regeneration in humans remains poorly understood,” he said.
This research shows that 48 hours of stimulation with small molecule inhibitors is sufficient to restore insulin production from damaged pancreatic cells.
JDRF Senior Research Fellow, Dr Keith Al-Hasani said the next step was to investigate the novel regenerative approach in a preclinical model. The aim is to develop these inhibitors as drugs to restore insulin production in people living with diabetes.
As the work progresses, so too does the need to translate rapidly. More than 530 million adults are living with diabetes, with that number expected to rise to 643 million by 2030.
About type 1 diabetes
Type 1 diabetes is where the native beta cell population responsible for insulin release has been the subject of autoimmune destruction. This condition requires patients to frequently measure their blood glucose levels and administer multiple daily insulin injections accordingly. Current treatments fail to effectively treat the disease without significant side effects which has led to the exploration of different therapeutic approaches.
About type 2 diabetes
Type 2 diabetes is a condition that has strong genetic and family-related (non-modifiable) risk factors and is also often associated with modifiable lifestyle risk factors. It is a condition in which the body becomes resistant to the normal effects of insulin and gradually loses the capacity to produce enough insulin in the pancreas. As a result, the pancreas responds by producing greater amounts of insulin. As insulin overproduction occurs over a long period of time, the insulin-producing cells in the pancreas wear themselves out. This means type 2 diabetes is a combination of ineffective insulin and not enough insulin.
Nästan var och varannan dag kommer info om hur användbar Reg Med är för sjukdomstillstånd idag svåra och i vissa fall obotbara,det med nuvarande medicinering och teknik. Dessa Australiensiska forskare kan vara på gång att lösa diabeteshelvetet för miljontals människor världen över.Ge dem 1 år till så har de kanske fått alla tillstånd som krävs för att dra igång produktion hos främst diabetespatienter i Australien. Sen lär övriga länder vilja dra igång liknande. Reg Med är odiskutabelt framtiden.
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
- New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses
- Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding
- Nobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical research
Wow!
SvaraRaderaFör er som vill ha en sammanfattning av studien. Detta är stort!
SvaraRaderahttps://www.diabetes.org.uk/about-us/news-and-views/research-shows-promise-restore-beta-cells-and-offer-type-1-diabetes-treatment-hope
In the study, researchers tested two cancer drugs are known as EZH2 inhibitors, called GSK 126 and Tazemetostat, in pancreas samples donated from a child and an adult with type 1 diabetes. The drugs have been approved by the US Food and Drug Administration (FDA) to treat other health conditions.
RaderaThey found that the drugs triggered cells found in the pancreas called ductal cells – which don’t normally produce insulin and aren’t victims of the type 1 diabetes immune attack – to behave like beta cells, and start producing insulin.
This process involves changing the ductal cell’s genetic ingredients, and a key player in this process is a protein called EZH2. The two drugs work by targeting this protein.
Tests showed that newly transformed beta cells were able to release insulin in response to sugar, just like real beta cells would. Although more research is now needed, the findings suggest that insulin production could one day be restored in people with type 1 diabetes by helping the pancreas to generate new beta cells.
Hej, i mina otränade öron inom området tycker jag detta låter lite som det Nextcell Pharma håller på med? Någon som vet om det finns några likheter eller stora skillnader? För övrigt ligger duktigt minus i Nextcell, -75% och greppar efter halmstrån...
SvaraRadera